AGNES HEYL: Open Payments
NPI 1174540918 · WESTMINSTER, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$241 in 12 payments from 8 companies in 2025. Trend: 2023 $306 · 2024 $215 · 2025 $241
Food & beverage: $241
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 3 | $57 |
| Teva Pharmaceuticals USA, Inc. | 2 | $37 |
| Supernus Pharmaceuticals, Inc. | 2 | $34 |
| Alkermes, Inc. | 1 | $27 |
| E.R. Squibb & Sons, L.L.C. | 1 | $24 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $23 |
| Lundbeck LLC | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $17 |
Products named: UZEDY, ABILIFY MAINTENA, Qelbree, ARISTADA, COBENFY, CAPLYTA, ABILIFY ASIMTUFII, REXULTI.
Industry payments across MD — which companies pay providers there.
